A blog about competition law and policy
On 21 July 2022 the CMA imposed fines of £63m on Pfizer and £6.7m on Flynn in relation to the excessive pricing of the generic drug phenytoin, an anti-epilepsy drug. This comes nearly six years on from the CMA’s first infringement decision in relation to the conduct. That first decision imposed fines of £84.2m on … Continue reading Phenytoin – was it worth it?
Excessive pricing, sham patents and private actions, please find below the antitrust enforcement developments in healthcare that caught our eye this summer. Three excessive pricing decisions and a statement of objections Are excessive pricing cases like London buses? You might think so after waiting for one for months only for four to appear practically at … Continue reading Developments in antitrust enforcement in healthcare that caught our eye this summer
The Thicket 